Skip to main content
29) { ?>
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

Will Federal Regulators APPROVE The Pfizer Jab?


Nothing says experimental more than a pending FDA approval.

People all over the country are hesitant to get the jab, and everyone who is concerned has every right. After all, these things aren’t even really approved by federal regulators yet….

This could all change in January though.

According to sources, we could see federal regulators approve Pfizer’s Covid-19 vaccine around January of 2022.

This may or may not cure vaccine hesitancy, but at this point people have such little faith in government institutions that an approval will probably have little effect.

If it were to be approved though, would you take the jab?

Take a look:

The Epoch Times presented us with a potential timeframe for the approval:

All three companies have asked for or intend to ask for full approval, which requires more data and a more thorough review.

Dr. Janet Woodcock, the acting commissioner of food and drugs for the FDA, said regulators are targeting January 2022 to be done with the review, but the target “does not mean approval will not happen before that time.”

“Quite to the contrary, the review of this BLA has been ongoing, is among the highest priorities of the agency, and the agency intends to complete the review far in advance” of that target date, she said in a statement.

Pfizer finished submitting the request for approval, formally known as the Biologics License Application (BLA), in May. It includes clinical data from a phase 3 clinical trial that Pfizer and its partner, BioNTech, said showed the jab was 91.3 percent effective against COVID-19 and 100 percent effective against severe disease.

Fox Business had more details:

The Advisory Committee on Immunization Practices (ACIP) plans to convene on July 22 to discuss “clinical considerations for additional doses in immunocompromised individuals,” according to a draft agenda posted ahead of the meeting.

The National Institutes of Health defines immunocompromised patients as those with “a reduced ability to fight infections and other diseases,” potentially caused by conditions like “AIDS, cancer, diabetes, malnutrition, and certain genetic disorders” or medicines or treatments like chemotherapy and organ transplants.

Some evidence has indicated immunocompromised individuals, who account for about 2.7% of the country’s population, mount a diminished protective immune response, even after two doses of vaccine. More specifically, one study showed 7-27 days after a second Pfizer dose, there was 75% protection against symptomatic COVID-19 among immunosuppressed patients, compared with 94% overall. The patients also saw less protection against infection at 71% versus 90% overall, after two Pfizer doses.

29) { ?>


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

29) { ?>

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!